Опыт применения эхоконтрастного препарата Соновью в дифференциальной диагностике опухолей почки. Часть 1

Sufficient experience of differential diagnostics of focal renal lesions according to contrast-enhanced ultrasound is accumulated in the world now, however, only the own experience of use of this agent gives the chance of accumulation of the corresponding knowledge and skills. Objective: to estimate the possibilities of SonoVue contrast agent for differential ultrasonic diagnostics of focal renal lesions and to compare the obtained data with results of morphology. Materials and methods. During the period from March, 2015 to September, 2016 at A.V. Vishnevsky Institute of surgery 47 patient with focal renal lesdions have been surveyed and were operated on. There were 27 (57.4%) men and 20 (42.6%) women aged from 19 up to 66 years. All patient carried out ultrasonography in B-mode, duplex scanning, threedimensional reconstruction of the ultrasonic image, and contrast-enhanced research with SonoVue agent was carried out also. All neoplasms were morphologically verified: clear cell carcinoma – 34 (72.4%); papillary cancer – 4 (8.5%); chromophobe cancer – 1 (2.1%); juxtaglomerular cell tumor – 1 (2.1%); oncocytoma – 1 (2.1%); neurogenic tumor – 1 (2.1%); adenoma – 2 (4.3%); chronic inflammatory infiltrate – 1 (2.1%); a cyst – 2 (4.3%). We consider to take up expedient separately questions of diagnosis of lightcellular cancer and rare forms of kidney and cellular cancer. Results. Part 1. Assessment of opportunities of SonoVue contrast agent at differential diagnosis of renal clear cell carcinoma. Ultrasonography in the B-mode, duplex scanning, three-dimensional reconstruction, doesn’t always allow to obtain accurate information on localization of renal tumor, and the nature of the lesion, therefore contrastenhanced ultrasonography with SonoVue agent was applied. Sensitivity, specificity and accuracy of сontrast-enhanced ultrasonography at diagnosis of renal clear cell carcinoma were 92%, 100%, 92%, respectively. Conclusion. Contrast-enhanced ultrasonography with SonoVue agent is rather cheap, doesn't bear beam load of the patient and isn't nephrotoxic owing to what it is expedient to include it in the protocol of inspection of patients with suspicion of renal cancer.